Progyny (PGNY) to Release Earnings on Thursday

Progyny (NASDAQ:PGNY) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Progyny to post earnings of $0.14 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Progyny (NASDAQ:PGNY) last posted its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The company had revenue of $269.94 million during the quarter, compared to analysts’ expectations of $274.08 million. During the same quarter last year, the firm earned $0.03 earnings per share. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Trading Up 0.7 %

Shares of NASDAQ PGNY opened at $32.29 on Thursday. Progyny has a twelve month low of $29.44 and a twelve month high of $44.95. The stock has a fifty day simple moving average of $35.51 and a 200-day simple moving average of $35.63. The stock has a market capitalization of $3.10 billion, a PE ratio of 52.08, a PEG ratio of 1.35 and a beta of 1.48.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PGNY shares. Truist Financial reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Progyny in a research note on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $48.00 price objective on shares of Progyny in a research note on Wednesday, February 28th. SVB Leerink began coverage on Progyny in a research note on Monday, February 26th. They set an “outperform” rating and a $49.00 target price for the company. Barclays began coverage on Progyny in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $48.00 target price for the company. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $48.30.

Insiders Place Their Bets

In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of Progyny stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the sale, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,323,012. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of Progyny stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the sale, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,323,012. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman David J. Schlanger sold 1,000 shares of Progyny stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.52, for a total value of $37,520.00. Following the sale, the chairman now directly owns 83,631 shares of the company’s stock, valued at $3,137,835.12. The disclosure for this sale can be found here. Insiders sold 120,515 shares of company stock valued at $4,570,131 in the last ninety days. Insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.